Friedrich Graf Finckenstein

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani et al. · Journal of Clinical Oncology · 2021 · 410 citations · Full text

Life Sciences, Immunology, Oncology +17

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Jason Chesney, Karl D. Lewis, Harriet M. Kluger et al. · Journal for ImmunoTherapy of Cancer · 2022 · 320 citations · Full text

Life Sciences, Immunology, Oncology +17

Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar Rhabdomyosarcomas

Elai Davicioni, Friedrich Graf Finckenstein, Violette Shahbazian et al. · Cancer Research · 2006 · 310 citations · Full text

Medicine, Molecular Biology, Oncology +14

Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of Diagnosis

Elai Davicioni, Michael J. Anderson, Friedrich Graf Finckenstein et al. · American Journal Of Pathology · 2009 · 296 citations · Full text

Medicine, Oncology, Pathology +17

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Leora Horn, Hossein Borghaei et al. · Journal of Clinical Oncology · 2015 · 147 citations

Medicine, Oncology, Pharmacotherapy +11